Two drugs under review by the FDA—dabrafenib and trametinib—seem to slow development of treatment resistance in patients with metastatic malignant melanoma.
http://www.pharmacytimes.com/news/Combatting-Treatment-Resistance-in-Metastatic-Melanoma-Therapy
Leave a Reply